


Certificate of Mailing:

The undersigned certifies that this correspondence is being sent via first-class mail, with adequate postage, in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, this 19th day of July, 2004.

(s)

  
Linda S. Evans



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Darrow et al. Atty. Docket: ORT-1560  
Serial No.: 10/041,054 Art Unit: 1652  
Filed: January 7, 2002 Examiner: William W. Moore  
For: DNA Encoding the Human Serine Protease T

Mail Stop AF  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Sir:

This Statement is supplemental to the Information Disclosure Statement filed with the above-identified application on January 7, 2002, and the Supplemental Information Disclosure Statement dated July 16, 2003. Pursuant to 37 C.F.R. § 1.56 and in accordance with 37 C.F.R. §§ 1.97-1.98, Applicant submits the accompanying Form PTO-1449 citing references relating to the application.

This Statement is being filed under the provisions of 37 C.F.R. § 1.97(d). Please charge the \$180.00 fee set forth at 37 C.F.R. § 1.17(p) to Deposit Account No. 10-0750 (a copy of this paper is enclosed; if any additional fees are required for the filing of this Statement, please charge such fees to the deposit account). The required statement as specified at 37 C.F.R. § 1.97(e) follows.

The references listed on the enclosed form were first cited in a counterpart European application in an official Communication not more than three months prior to the filing of this Statement. A copy of the Communication from the EPO, which is dated May 12, 2004, is enclosed.


Copies of the references listed on the enclosed Form PTO-1449 are enclosed. Each reference is in the English language.

This Statement should not be construed as an admission that any information provided herewith is material as that term is defined in 37 C.F.R. § 1.56(b) or that the cited reference qualifies as prior art. This Statement should not be construed as a representation that a search has been made, or that information and more material does not exist.

The Examiner is respectfully requested to initial the citation on the Form PTO-1449 to confirm consideration of the reference.

Respectfully submitted,

Date: July 19, 2004

  
Linda S. Evans  
Reg. No. 33,873

Johnson & Johnson  
One Johnson & Johnson Plaza  
New Brunswick, New Jersey 08933-7003  
(858) 320-3406

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

SERIAL NO.

ORT-1560

10/041,054

APPLICANT

Darrow et al.

FILING DATE

January 7, 2002

GROUP ART UNIT

1652

**INFORMATION DISCLOSURE  
CITATION BY APPLICANT**

(Use several sheets if necessary)

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	INVENTORS	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

**FOREIGN PATENT DOCUMENTS**

	DOCUMENT NUMBER	DATE	COUNTRY/REGION	CLASS	SUBCLASS	TRANSLATION (if applicable)
WO	0 1 3 5 4 4 0	17 May 2001	WIPO (PCT)			

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

	Adams et al., "Initial Assessment Of Human Gene Diversity And Expression Patterns Based Upon 83 Million Basepairs Of cDNA Sequence", Database EMBL Accession No. AA321681, 1997.
	Hillier et al, "WashU-NCI Human EST Project", Database EMBL Accession No. AI272325, 1998.

EXAMINER

DATE CONSIDERED

**EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.